A CU research team led by Kasey L. Couts developed a human melanoma cell line containing an AGK-BRAF fusion. The cell line, called MB1692, can be used be used for drug screening, basic science research, and biological assays. The research team used this and other cell lines to investigate the role of BRAF mutations and fusion genes in melanoma cell proliferation, 3D invasion, and response to therapeutic small molecules.
Turner JA, Bemis JGT, Bagby SM, et al. BRAF fusions identified in melanomas have variable treatment responses and phenotypes. Oncogene. 2019;38(8):1296-1308. doi: 10.1038/s41388-018-0514-7.